Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma

Purpose. To evaluate the efficacy and toxicity of adjuvant combination of sequential chemotherapy followed by radiotherapy in uterine papillary serous carcinoma (UPSC). Methods and materials. From April 1994 to June 2003, 26 patients (median age 61.7 years, range 46.9-78.4) with UPSC were treated with a platinum-based chemoradiation protocol after definitive surgery. 9 patients were assigned as stage 1 (35%), 4 were stage 11 (15%), 11 were stage Ill (42%), and 2 were stage IV (8%) according to the FIGO staging for gynecological cancers. All patients underwent total hysterectomy, salpingo-oophorectomy, pelvic +/- perioartic lymph nodes dissection/sampling, omentectomy, and peritoneal washing. The adjuvant chemoradiation protocol consists of 4 cycles of platnum-based chemotherapy followed by pelvic irradiation and vaginal vault brachytherapy. In selected stage I patients with no or minimal myometrial invasion, only vault brachytherapy was given after adjuvant chemotherapy Results. After a median follow-up of 28 months (range 9-113 months), 14 (54%) patients were alive and free of disease. 12 Out of these 14 patients were FIGO stage 1/11. 9 patients (35%) had died (8 from distant metastases). The Kaplan-Meier 2-year and 5-year Survival estimates were 69.5% and 57%, respectively. Only 4 (15%) patients had pelvic recurrence. None of the patients developed local vault recurrence. The treatment was well tolerated, only 1 patient developed congestive cardiac failure from the chemotherapy and 6 patients had grade 2 peripheral neuropathy on follow-up. Conclusion. In our series of UPSC patients treated with adjuvant chemotherapy followed by radiotherapy, local control call be achieved in a majority of patients. Distant failure remains the major cause of mortality. Further investigations into finding a more effective systemic therapy are required if improvement in outcome for this form of uterine cancer is to be achieved. (c) 2005 Elsevier Inc. All rights reserved.